How Cysts Grow

The Two Driving Forces of Cyst Growth

Once a cyst forms, its continued growth is driven by two core mechanisms:

1. Proliferation of cyst-lining epithelial cells: The cAMP-ERK and mTOR pathways drive continuous division of cyst-wall cells, increasing the surface area of the cyst wall.
2. Fluid secretion into the cyst lumen: The CFTR chloride channel mediates chloride secretion, with sodium following passively and water entering by osmosis, increasing cyst volume.

These two processes reinforce each other — more cells produce more secretory surface area, and a larger lumen provides more room for growth. This is why cysts grow exponentially, not linearly.

The cAMP-PKA Pathway: The Core Engine of Cyst Growth

In polycystic kidney cells, cAMP drives cyst growth through two downstream pathways:

• B-Raf → MEK → ERK pathway: Promotes cell proliferation. In normal cells, cAMP inhibits B-Raf, but in polycystic kidney cells the reduced intracellular calcium reverses this response, and cAMP instead activates B-Raf.
• PKA → CFTR pathway: PKA phosphorylates and opens the CFTR chloride channel, driving fluid secretion.

The primary source of cAMP is activation of the vasopressin V2 receptor (V2R). Vasopressin binds to V2R on the surface of collecting duct principal cells, activating adenylyl cyclase 6 (AC6) via the Gs protein, which generates large amounts of cAMP. This is why blocking V2R (tolvaptan) can effectively slow cyst growth.

However, completely blocking the cAMP-PKA pathway is not feasible — cAMP has many important functions in normal cells. Therefore, research is exploring the possibility of targeting downstream cAMP pathways (such as ERK and CFTR) to inhibit cyst growth while preserving normal cAMP function.

The CFTR Chloride Channel: The Molecular Basis of Fluid Secretion

The key to cyst fluid secretion is the CFTR (cystic fibrosis transmembrane conductance regulator) chloride channel. In normal collecting duct cells, CFTR participates in chloride secretion to maintain electrolyte balance of tubular fluid. In polycystic kidney disease:

1. cAMP-PKA phosphorylates CFTR, causing it to open.
2. Chloride ions are secreted from cyst-wall cells into the cyst lumen.
3. Sodium ions follow chloride via the paracellular pathway.
4. Water follows the salt into the cyst lumen by osmosis.

This process is similar to normal renal tubular fluid secretion, but in cysts it has lost its regulatory control and continues unabated. CFTR inhibitors can reduce cyst fluid secretion in vitro, but clinical application is not yet mature.

Metabolic Reprogramming: The Energy Source of Cyst Cells

The metabolic pattern of cyst cells undergoes significant changes, similar to the Warburg effect in tumor cells:

• Enhanced aerobic glycolysis: ATP is preferentially produced through glycolysis, even under aerobic conditions. This leads to increased glucose consumption and lactate production.
• Suppressed mitochondrial oxidative phosphorylation: Mitochondrial function declines, and fatty acid oxidation decreases.
• Glutamine dependence: Cyst cells rely on glutamine as an energy source and biosynthetic precursor.

This metabolic alteration is driven by mTORC1, HIF-1α, c-MYC, and others. Gene expression analysis of human PKD1 kidney tissue has confirmed these features. The significance of metabolic reprogramming:

• It provides a theoretical basis for dietary interventions — carbohydrate restriction and ketogenic diets slow cyst growth in animal models, but human evidence is insufficient.
• It provides targets for novel drugs — GLP-1 receptor agonists (semaglutide) slow cyst growth in animal models by regulating glycolysis and mitochondrial function; human trials are underway.

Impaired Autophagy: Reduced Cellular Cleanup Capacity

Autophagy is the mechanism by which cells clear damaged organelles and proteins. In polycystic kidney disease, abnormal mTOR activation suppresses autophagic flux, leading to intracellular waste accumulation and exacerbating cellular stress and injury.

In a zebrafish pkd1 mutant model, autophagy activators (rapamycin, carbamazepine, minoxidil) significantly inhibited cyst formation. This suggests that autophagy is a potential therapeutic target for ADPKD, but it remains in the preclinical stage.

From Cysts to Fibrosis: The Critical Turning Point

Cyst growth itself is not the direct cause of kidney function loss — even if the kidneys are filled with cysts, if the cysts do not compress normal tissue, kidney function can be maintained. The core mechanism of kidney function loss is ischemia and fibrosis caused by cyst compression.

Compression and Ischemia

As cysts enlarge, they compress surrounding structures:

• Renal tubules: Compressed tubules atrophy and become occluded, losing function.
• Peritubular capillaries: Reduced blood flow leads to local ischemia, and hypoxia further promotes fibrosis.
• Lymphatic vessels: Lymphatic drainage is obstructed, worsening interstitial edema and inflammation.

Interstitial Fibrosis

Ischemia and inflammation activate interstitial fibroblasts, which transform into myofibroblasts that secrete large amounts of collagen and extracellular matrix, forming interstitial fibrosis. Fibrotic tissue replaces normal renal interstitium, further reducing blood flow and oxygen supply, creating a vicious cycle.

Tubular atrophy and interstitial fibrosis are irreversible structural damage. This is why eGFR decline typically appears only after many years of cyst growth — when structural damage accumulates to a certain threshold, kidney function begins to decline rapidly.

Structural Progression Precedes Functional Decline

The CRISP prospective study confirmed that total kidney volume (TKV) growth in ADPKD precedes eGFR decline by many years. The annual TKV growth rate is a key predictor of future eGFR decline. This is why:

• Regular monitoring of TKV is important — it can identify rapid progressors before kidney function declines.
• Tolvaptan is more effective in early-stage patients — intervening when structural damage is still reversible.
• The PROPKD score combines TKV growth rate for risk stratification — identifying patients who need targeted therapy.

Factors Affecting Cyst Growth Rate

Cyst growth rates vary greatly between patients. Factors affecting growth rate include:

• Genotype: PKD1 truncating mutations > PKD1 missense mutations > PKD2 mutations.
• Baseline TKV: Larger baseline kidney volume correlates with faster growth.
• Blood pressure: Hypertension is associated with faster cyst growth.
• Sodium intake: High urinary sodium excretion is associated with faster TKV growth and eGFR decline.
• Vasopressin levels: Elevated copeptin predicts faster progression.
• HDL cholesterol: Low HDL is associated with faster progression.
• Age and sex: Males typically progress slightly faster than females.

Why Early Intervention Matters

Because cyst growth is exponential and structural damage (fibrosis) is irreversible, early intervention is critical:

• When cysts are smaller and fibrosis is less extensive, blocking the V2R-cAMP pathway can maximally slow cyst growth.
• Once extensive fibrosis has formed, even if cyst growth is halted, the lost kidney function cannot be recovered.
• This is why the KDIGO 2025 guideline recommends early initiation of tolvaptan for patients at high risk of rapid progression.

However, early intervention also requires trade-offs — the side effects of tolvaptan (polyuria and thirst, hepatotoxicity) and its impact on quality of life. Whether to initiate treatment requires a shared decision between you and your doctor, based on your risk stratification and personal preferences.

← Back to Knowledge Base